Sprout Pharms Drug Patent Portfolio
Sprout Pharms owns 1 orange book drug protected by 4 US patents Given below is the list of Sprout Pharms's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7151103 | Method of treating female hypoactive sexual desire disorder with flibanserin | 09 May, 2028 | Active |
| US8227471 | Treating sexual desire disorders with flibanserin | 09 May, 2023 | Expired |
| US9468639 | Treating sexual desire disorders with flibanserin | 16 Oct, 2022 | Expired |
| US7420057 | Stable polymorph of flibanserin | 01 Aug, 2022 | Expired |
Latest Legal Activities on Sprout Pharms's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Sprout Pharms.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 12th Year, Large Entity | 10 Jan, 2024 | US8227471 |
|
Patent Term Extension Certificate
Critical
| 19 Nov, 2021 | US7151103 |
| FITF set to NO - revise initial setting | 05 Mar, 2021 | US7151103 |
| Notice of Final Determination -Election Required | 05 Mar, 2021 | US7420057 |
| Notice of Final Determination -Election Required | 05 Mar, 2021 | US7151103 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 07 Apr, 2020 | US9468639 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 24 Feb, 2020 | US7420057 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 14 Jan, 2020 | US8227471 |
|
Email Notification
Critical
| 08 Oct, 2019 | US7151103 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 08 Oct, 2019 | US7151103 |
|
Correspondence Address Change
Critical
| 07 Oct, 2019 | US7151103 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 03 Oct, 2019 | US7420057 |
|
Correspondence Address Change
Critical
| 02 Oct, 2019 | US7420057 |
|
FDA Final Eligibility Letter
Critical
| 03 Jul, 2019 | US7420057 |
|
FDA Final Eligibility Letter
Critical
| 03 Jul, 2019 | US7151103 |
Sprout Pharms's Family Patents
Sprout Pharms drugs have patent protection in a total of 31 countries. It's US patent count contributes only to 23.2% of its total global patent coverage. 23 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click
below to unlock the full patent family tree.
Sprout Pharms Drug List
Given below is the complete list of Sprout Pharms's drugs and the patents protecting them.
1. Addyi
Addyi is protected by 4 patents, out of which 3 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7151103 | Method of treating female hypoactive sexual desire disorder with flibanserin |
09 May, 2028
(3 years from now)
| Active |
| US8227471 | Treating sexual desire disorders with flibanserin |
09 May, 2023
(1 year, 5 months ago)
| Expired |
| US9468639 | Treating sexual desire disorders with flibanserin |
16 Oct, 2022
(1 year, 11 months ago)
| Expired |
| US7420057 | Stable polymorph of flibanserin |
01 Aug, 2022
(2 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Addyi's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List